Andrew Moreno

Editor

Articles by Andrew Moreno

Andrew MorenoSickle Cell Disease | April 29, 2025
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
Adrián Mosquera Orgueira, MD, PhDMyelofibrosis | April 25, 2025
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
Andrew MorenoHemophilia | April 23, 2025
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
Andrew MorenoHematology | April 21, 2025
Malignant neoplasm-associated hemophagocytic lymphohistiocytosis, COVID-19, and CAR T-cell therapy can each initiate CS.
Andrew MorenoAnemia | April 15, 2025
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
Andrew MorenoVTE | April 15, 2025
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
Andrew MorenoSickle Cell Disease | April 8, 2025
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
Ivan Maillard, MD, PhDHematology | April 8, 2025
ASH Awards Commitee Chair Ivan Maillard, MD, PhD, and prior awardee Rinku Majumder, PhD, tell of the Grant's positive impact.
Andrew MorenoMDS | April 2, 2025
The agent recalibrates the immune system to attack tumors and increases cancer susceptibility to standard of care therapy.
Andrew MorenoMDS | March 31, 2025
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
Andrew MorenoHematology | March 26, 2025
Azercabtagene zapreleucel is an allogeneic CD-19-targeting therapy combining lymphodepletion chemotherapy with interleukin-2.
Andrew MorenoPolycythemia Vera | March 25, 2025
The hepcidin mimetic increased hematocrit control and reduced both phlebotomy need and symptoms in a phase 2 trial.
Andrew MorenoPolycythemia Vera | March 19, 2025
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
Andrew MorenoAnemia | March 18, 2025
The oral agent exhibited promising hemoglobin response performance and safety in this stage of an ongoing phase 2/3 study.
Andrew Morenovon Willebrand Disease | March 17, 2025
The first-in-class agent operates by increasing both von Willebrand factor and factor VIII levels in patients.
Andrew MorenoThrombocytopenia | March 14, 2025
Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
Andrew MorenoThrombosis | March 12, 2025
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
Andrew MorenoHematology | March 10, 2025
Clinical trials are ongoing to evaluate this orally available, selective inhibitor of XPO1 as part of combination regimens.
Andrew MorenoMyelofibrosis | March 6, 2025
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Andrew MorenoHematology | March 5, 2025
Neil Love, MD, has moderated an expert panel discussing current practice and recent data behind these treatments for NHL.